Royalty Pharma plc Quarterly Retained Earnings (Accumulated Deficit) in USD from Q4 2019 to Q4 2024

Taxonomy & unit
us-gaap: USD
Description
The cumulative amount of the reporting entity's undistributed earnings or deficit.
Summary
Royalty Pharma plc quarterly Retained Earnings (Accumulated Deficit) history and growth rate from Q4 2019 to Q4 2024.
  • Royalty Pharma plc Retained Earnings (Accumulated Deficit) for the quarter ending December 31, 2024 was $2.85B, a 13% increase year-over-year.
Retained Earnings (Accumulated Deficit), Quarterly (USD)
Retained Earnings (Accumulated Deficit), YoY Quarterly Growth (%)
Period Value YoY Chg Change % Date Report Filed
Q4 2024 $2.85B +$328M +13% Dec 31, 2024 10-K 2025-02-12
Q3 2024 $2.76B +$630M +29.5% Sep 30, 2024 10-Q 2024-11-06
Q2 2024 $2.38B +$125M +5.56% Jun 30, 2024 10-Q 2024-08-08
Q1 2024 $2.43B +$211M +9.5% Mar 31, 2024 10-Q 2024-05-09
Q4 2023 $2.52B +$553M +28.1% Dec 31, 2023 10-K 2025-02-12
Q3 2023 $2.13B -$370M -14.8% Sep 30, 2023 10-Q 2023-11-08
Q2 2023 $2.25B -$193M -7.9% Jun 30, 2023 10-Q 2023-08-08
Q1 2023 $2.22B -$7.87M -0.35% Mar 31, 2023 10-Q 2023-05-09
Q4 2022 $1.96B -$290M -12.9% Dec 31, 2022 10-K 2024-02-15
Q3 2022 $2.5B +$184M +7.93% Sep 30, 2022 10-Q 2022-11-08
Q2 2022 $2.45B +$154M +6.73% Jun 30, 2022 10-Q 2022-08-04
Q1 2022 $2.22B +$301M +15.6% Mar 31, 2022 10-Q 2022-05-05
Q4 2021 $2.26B +$335M +17.4% Dec 31, 2021 10-K 2023-02-15
Q3 2021 $2.32B +$514M +28.4% Sep 30, 2021 10-Q 2021-11-10
Q2 2021 $2.29B +$721M +45.9% Jun 30, 2021 10-Q 2021-08-11
Q1 2021 $1.92B Mar 31, 2021 10-Q 2021-05-11
Q4 2020 $1.92B -$905M -32% Dec 31, 2020 10-K 2022-02-15
Q3 2020 $1.81B Sep 30, 2020 10-Q 2020-11-12
Q2 2020 $1.57B Jun 30, 2020 10-Q 2020-08-12
Q4 2019 $2.83B Dec 31, 2019 10-K 2021-02-24
* An asterisk sign (*) next to the value indicates that the value is likely invalid.